Wed, 31 July 2013
In the July 2013 edition of the Legal Current podcast, we discuss:
Legal Trends & Insights: The impact of the new RTA Claims Portal on personal injury claims in the UK
Legal News: An interview with Prof. Ronald Rotunda of Chapman University on the recently concluded US Supreme Court 2012-13 term
News From Thomson Reuters: Results from a new survey of law enforcement on cybercrime
On the Legal Blogs: Did a new mother fail a drug test because of poppy seed bagel?
Mon, 22 July 2013
Predictive coding can provide major benefits when dealing with high volumes of electronically-stored information (ESI). But at the same time, it is far from a “silver bullet” in handling ESI.
There are four essential concepts that emerge when examining matters that have successfully and unsuccessfully utilized predictive coding.
Ed Sohn, assistant vice president for professional and consulting services at Pangea3 has written a white paper examining “The Four Pillars of an Effective Predictive Coding Workflow.”
Mon, 15 July 2013
Thomson Reuters Company Investigator helps users find information on companies to assist with business development, litigation, due diligence and a host of other applications. Company Investigator accesses more than 30 million company profiles, including 20 million hard-to-find private companies, including general company information, subsidiary data, legal disputes, secretary of state filings, regulatory filings and material agreements.
Company Investigator is available on WestlawNext and presents information in a manner that makes it easy to analyze corprorate "family tree" structures, relationships among corporate entities, and other company-related information such as recently filed court dockets, bankruptcy filings and more.
Tue, 2 July 2013
In the case of Association for Molecular Pathology v. Myriad Genetics, Inc. the U.S. Supreme Court unanimously ruled that a naturally occurring DNA segment is a product of nature and not patent eligible merely because it has been isolated, but synthetic complementary DNA ("cDNA") is patent eligible because it is not naturally occurring.
The distinction is a critical one, as it opens the door for broad application certain genetic testing, while preserving important patent rights for the biotechnology industry.
Jorge Goldstein, Ph.D, of Sterne Kessler Goldstein & Fox PLLC, who is one of the leading pioneers in biotechnology patent law, discusses both legal and scientific ramifications of the case in this podcast interview.